The new coronavirus treatment drug monoravir capsules completed the first batch of import customs clearance in the Shanghai Waigaoqiao Free Trade Zone

The new coronavirus treatment drug monoravir capsules completed the first batch of import customs
clearance in the Waigaoqiao Free Trade Zone in Shanghai on the 13th.

On the same day, Sinopharm Holdings Co.
, Ltd.
held the China premiere ceremony
of the drug at the Shanghai Waigaoqiao Bonded Branch Center.
The first batch of drugs totaling 15.
5 tons, after being inspected and released by the customs of Shanghai Waigaoqiao Free Trade Zone, completed the import clearance procedures and left the zone in the afternoon of the same day, and was released into the Chinese market
in time.

On December 29, 2022, in accordance with the relevant provisions of the Drug Administration Law, the State Food and Drug Administration of China conducted emergency review and approval in accordance with the special approval procedure for drugs, and conditionally approved the import registration
of monogravir capsules, Merck's new coronavirus treatment drug.

After the first batch of drugs entered the country, Shanghai Pudong Airport Customs specially formulated a customs clearance supervision plan for the airport and port to facilitate the timely entry of drugs into the bonded zone
.
The customs of Waigaoqiao Free Trade Zone tracks the import plan of goods throughout the process, makes a customs clearance guarantee plan in advance, and provides "7×24" hours online consulting services and bayonet "green channels"
.
It only takes 5 hours and 22 minutes
from the acceptance of the declaration to the smooth entry into the warehouse in the bonded zone.

According to information from Sinopharm, after the first batch of monoravir capsules successfully passed the import process, in the future, the company will also carry out the import of this type of new coronavirus treatment drugs in batches according to market demand, and go all out to ensure
the supply of medical materials.